Company Active LTD

Company profile

Corryn Biotechnologies Ltd

Corryn Biotechnologies

Corryn Biotechnologies Ltd is a UK company with status active founded in 2021 based in Wales.

CRN
13184878
Founded
2021
Age
5

Overview

Legal name
CORRYN BIOTECHNOLOGIES LTD
Region
Wales
Registered address
BAY TECHNOLOGY CENTRE CENTRAL AVENUE
BAGLAN
PORT TALBOT
WALES
SA12 7AX
Insolvency history
No

Latest accounts

Financial period: 1 Mar 2025 to 30 Sep 2025

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
4

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Jun
2027

Accounts due

Accounts Due

Next accounts due date

14 Feb
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Jan
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Sep
2025

Accounts filed

Accounts

Last accounts made up date

01 Oct
2024

Accounts With Accounts Type Micro Entity

Accounts Analysed

AA | Transaction MzQzNzk0NTMyN2FkaXF6a2N4

Published 01 Oct 2024 10:58

08 Feb
2021

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2023
Funded years
2023, 2026
Age at first award
2 years

Projects

2026 Collaborative R&D Lead participant

Advanced Tissue Repair - Revolutionising Chronic Wound Care

1 Feb 2026 to 31 Jul 2027

Awarded
£499,857
Total cost £714,081

Corryn is addressing urgent challenges of chronic wound care: one of the most critical unsolved medical challenges, with no satisfactory treatments for the 3.8m sufferers in the UK and 160m worldwide. Our Advanced Tissue Repair (ATR) Platform is the world's first resorbable dressing ("the ATR Matrix") to be fabricated directly at the wound using our novel...

2023 Grant for R&D Lead participant

Advanced Wound Healing Dressings with Active Indicatior of Bacterial Infection

1 Jun 2023 to 30 Nov 2023

Awarded
£49,948
Total cost £49,948

Every year, the NHS spends £8 billion on wound care. Of this budget, two thirds, or £5.6 billion is spent on the treatment of chronic and complex wounds such as venous leg ulcers, and non-healing diabetic wounds. GP's, podiatrists, community, and hospital staff all respond daily to the recurrent needs of patients whose chronic wounds require staff time, d...

Product types

Collaborative R&D Grant for R&D